Wells Fargo & Company Acurx Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.94 - $4.81 $11 - $28	6 Added 7.41%	87 $0
Q4 2023 Feb 09, 2024	BUY	$1.28 - $5.76 $5 - $23	4 Added 5.19%	81 $0
Q3 2023 Nov 13, 2023	BUY	$1.41 - $2.55 $16 - $30	12 Added 18.46%	77 $0
Q2 2023 Aug 15, 2023	BUY	$2.47 - $3.53 $7 - $10	3 Added 4.84%	65 $0
Q1 2023 May 12, 2023	BUY	$3.06 - $4.5 $3 - $4	1 Added 1.64%	62 $0
Q4 2022 Feb 13, 2023	BUY	$2.75 - $4.1 $8 - $12	3 Added 5.17%	61 $0
Q3 2022 Nov 14, 2022	BUY	$3.0 - $4.78 $120 - $191	40 Added 222.22%	58 $0
Q2 2022 Aug 12, 2022	BUY	$2.42 - $4.0 $4 - $8	2 Added 12.5%	18 $0
Q4 2021 Feb 14, 2022	BUY	$4.02 - $5.64 $4 - $5	1 Added 6.67%	16 $0
Q3 2021 Nov 15, 2021	BUY	$3.77 - $6.18 $56 - $92	15 New	15 $0

1.25M

9.3K

9.7K

Ticker ACXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,556,600
Market Cap $9.82M
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.